156 related articles for article (PubMed ID: 36942344)
1. [Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients].
Wang Z; Wang WJ; Ding XY; Lu P; Zhu LM; Liu Q; Lu W
Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Mar; 44(3):470-476. PubMed ID: 36942344
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
Marks SM; Mase SR; Morris SB
Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
[TBL] [Abstract][Full Text] [Related]
3. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.
Bamrah S; Brostrom R; Dorina F; Setik L; Song R; Kawamura LM; Heetderks A; Mase S
Int J Tuberc Lung Dis; 2014 Aug; 18(8):912-8. PubMed ID: 25199004
[TBL] [Abstract][Full Text] [Related]
4. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis.
Lanoix JP; Betoudji F; Nuermberger E
Antimicrob Agents Chemother; 2014; 58(4):2316-21. PubMed ID: 24492372
[TBL] [Abstract][Full Text] [Related]
5. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
[TBL] [Abstract][Full Text] [Related]
6. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
[TBL] [Abstract][Full Text] [Related]
7. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
Cui X; Gao L; Cao B
Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
[TBL] [Abstract][Full Text] [Related]
8. Newer Drugs for Tuberculosis Prevention and Treatment in Children.
Marais BJ
Indian J Pediatr; 2019 Aug; 86(8):725-731. PubMed ID: 30707347
[TBL] [Abstract][Full Text] [Related]
9. Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China.
Zhao B; Liu C; Fan J; Ma A; He W; Hu Y; Zhao Y
Microbiol Spectr; 2022 Oct; 10(5):e0240521. PubMed ID: 36214695
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the screening and treatment of latent multidrug-resistant tuberculosis infection.
Deng G; Zhang P; Lu H
Drug Discov Ther; 2022 May; 16(2):52-54. PubMed ID: 35466125
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.
Kasaie P; Pennington J; Gupta A; Dowdy DW; Kendall EA
Clin Infect Dis; 2024 Jan; 78(1):133-143. PubMed ID: 37724763
[TBL] [Abstract][Full Text] [Related]
12. Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis.
Cain KP; Nelson LJ; Cegielski JP
Int J Tuberc Lung Dis; 2010 Mar; 14(3):269-74. PubMed ID: 20132616
[TBL] [Abstract][Full Text] [Related]
13. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
[TBL] [Abstract][Full Text] [Related]
14. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
Tembo BP; Malangu NG
BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
[TBL] [Abstract][Full Text] [Related]
16. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
[TBL] [Abstract][Full Text] [Related]
17. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
Fox GJ; Nguyen CB; Nguyen TA; Tran PT; Marais BJ; Graham SM; Nguyen BH; Velen K; Dowdy DW; Mason P; Britton WJ; Behr MA; Benedetti A; Menzies D; Nguyen VN; Marks GB
BMJ Open; 2020 Jan; 10(1):e033945. PubMed ID: 31900274
[TBL] [Abstract][Full Text] [Related]
18. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
19. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
[TBL] [Abstract][Full Text] [Related]
20. Treatment guidelines for latent tuberculosis infection.
;
Kekkaku; 2014 Jan; 89(1):21-37. PubMed ID: 24654427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
